This session explores the evolving paradigm of cardio-renal-metabolic care, highlighting how SGLT2 inhibitor and DPP-4 inhibitor combinations can improve outcomes in patients with type 2 diabetes and associated co-morbidities. It focuses on mechanisms, patient selection, real-world evidence, and practical strategies to achieve comprehensive heart, kidney, and metabolic protection in routine clinical practice.